Mepolizumab biosimilar (CTTQ Pharma) | Interleukin Related interleukin-related.com

Product Name :
Mepolizumab biosimilar (CTTQ Pharma)

Search keywords :
Mepolizumab

drugId :
null

Target Vo:
Interleukin-5

Target Vo Short Name :
IL5

Moa_Name:
Interleukin-5 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group

Active Company_Name :
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd

Active Indication_Name:
Lymphohistiocytosis, Hemophagocytic

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
FGFR1 Oncogene Partner Antibody
GFAP Antibody (YA755)
EIF2A Antibody: EIF2A Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 65 kDa, targeting to EIF2A. It can be used for WB,IHC-P assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts